<--- Back to Details
First PageDocument Content
European Medicines Agency / European Cancer Organisation / Neuroblastoma / European Journal of Cancer / International Society of Paediatric Oncology / Cancer research / Medicine / Oncology / Cancer organizations
Date: 2013-10-09 09:12:26
European Medicines Agency
European Cancer Organisation
Neuroblastoma
European Journal of Cancer
International Society of Paediatric Oncology
Cancer research
Medicine
Oncology
Cancer organizations

SIOP EUROPE RESPONSE TO THE EUROPEAN COMMISSION PUBLIC CONSULTATION ON EXPERIENCE ACQUIRED AS A RESULT OF THE PAEDIATRIC REGULATION th November[removed]

Add to Reading List

Source URL: ec.europa.eu

Download Document from Source Website

File Size: 192,19 KB

Share Document on Facebook

Similar Documents

1. Sautter BM, Wessely R, Bihl H. Comparison of systemic radiotherapy with I-131labeled monoclonal antibody BW575/9 to external beam radiotherapy in human neuroblastoma xenografts. Strahlenther Onkol 1993;169:.

1. Sautter BM, Wessely R, Bihl H. Comparison of systemic radiotherapy with I-131labeled monoclonal antibody BW575/9 to external beam radiotherapy in human neuroblastoma xenografts. Strahlenther Onkol 1993;169:.

DocID: 1ukO2 - View Document

Numeric	
  Key	
  of	
  Factor	
  levels	
  for	
  extraction	
  parameters	
  	
   Quality of Animal Experiments in Anti-Angiogenic Cancer Drug Development – A Systematic Review Marianne Isabelle Martic-Kehl,

Numeric  Key  of  Factor  levels  for  extraction  parameters     Quality of Animal Experiments in Anti-Angiogenic Cancer Drug Development – A Systematic Review Marianne Isabelle Martic-Kehl,

DocID: 1qWRv - View Document

ANTI-TROPOMYOSIN AGENTS ENHANCE THE ANTITUMOR EFFECTIVENESS OF MICROTUBULE INHIBITORS IN PRECLINICAL MODELS OF NEUROBLASTOMA. JUSTINE STEHN1,2, MARK CURRIER3, DUO CHEN3, BROOKE NARTKER3, ELEANOR EIFFE1, ANDREW HEATON1,2,

ANTI-TROPOMYOSIN AGENTS ENHANCE THE ANTITUMOR EFFECTIVENESS OF MICROTUBULE INHIBITORS IN PRECLINICAL MODELS OF NEUROBLASTOMA. JUSTINE STEHN1,2, MARK CURRIER3, DUO CHEN3, BROOKE NARTKER3, ELEANOR EIFFE1, ANDREW HEATON1,2,

DocID: 1qUPq - View Document

www.edoriumjournals.com  CASE REPORT PEER REVIEWED | OPEN ACCESS

www.edoriumjournals.com CASE REPORT PEER REVIEWED | OPEN ACCESS

DocID: 1qNSk - View Document

May 2016 29th April, 2015 INVESTOR FACT SHEET Business Summary Novogen is a drug development company focused on

May 2016 29th April, 2015 INVESTOR FACT SHEET Business Summary Novogen is a drug development company focused on

DocID: 1qNjw - View Document